GEN Exclusives

More »

GEN News Highlights

More »
Jul 22, 2009

DxS and Horizon Team Up to Evaluate Former’s Companion Diagnostic for Anti-EGFR Therapy

  • Horizon Discovery and DxS entered a collaboration through which Horizon will generate a panel of human isogenic X-Man™ (mutant and normal) cell lines to help evaluate the effectiveness of DxS’ TheraScreen K-RAS Mutation Kits. 

    The TheraScreen K-RAS Mutation Kit is a companion diagnostic designed for use in combination with targeted anti-EGFR therapies for colorectal cancer, such as Amgen’s Vectibix™ (panitumumab) and Merck Serono Erbitux™, which is marketed by Bristol-Myers Squibb and ImClone. The kit detects mutations in a cancer patient’s K-RAS gene and can identify patients who are most likely to respond to anti-EGFR treatment.

    “Our initial focus will be on evaluating new diagnostic kits from DxS using isogenic human mutant versus normal DNA controls, which we feel represent  a gold-standard means of benchmarking companion diagnostics where mutations often need to be detected in humans with a background of excess isogenic normal DNA,” explains Horizon’s CEO, Chris Torrance Ph.D.
     
    The EMEA has already made the testing of all colon cancer patients for resistance genes compulsory before EGFR-targeted treatments can be prescribed, and the American Society of Clinical Oncologists (ASCO) is pushing for the adoption of similar guidelines, the companies note.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?